A strong platform for profitable growth
- Revenue increased by 18 per cent to EUR 331.7m (281.3) with organic growth of 11 per cent
- Adjusted EBITA reached EUR 87.3m (73.4) at a margin of 26.3 per cent (26.1)
- Operating profit (EBIT) reached EUR 41.3m (39.4) including EUR 8m negative impact from litigation claim valuation adjustment
- Profit for the period totalled EUR 10.5m (-7.2)
- Earnings per share before and after dilution EUR 0.02 (-0.02)
- Cash flow from operating activities of EUR -28.6m (25.3) impacted by the litigation payment in the second quarter, excluding this EUR 37.1m.
"In a year characterized by geopolitical uncertainty and a tough macroeconomy, Vimian stayed close to its customers and accelerated organic growth to 11 per cent, ahead of the animal health market. The adjusted EBITA margin improved to 26.3 per cent as Vimian progressed integration of acquired companies and efficiency measures deliver results", says Patrik Eriksson, CEO of Vimian Group.
Revenue for the fourth quarter increased by 9 per cent to EUR 82.5m (75.5) with organic growth of 7 per cent. Adjusted EBITA reached EUR 22.6m (18.0) at a margin of 27.5 per cent (23.9).
"We deliver a solid fourth quarter with continued good growth and improved profitability. Looking ahead, Vimian's overall strategy remains unchanged, and we will continue build strong global market positions in niches of the animal health market with unmet medical needs. Entering 2024, we continue to grow organically at high single digits, and see potential for some M&A discussions to pick up momentum during first half of this year. I see significant potential for value creation going forward through both organic and acquisition driven growth", says Patrik Eriksson.
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50046536
To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q4-report-2023
Related presentation materials will be available on Vimian's website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, has 1,000 employees and annual revenues of approximately EUR 330 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.
This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-15 07:45 CET.
